PA, NJ, DE-Israel Life Sciences Conference

Israeli Company Survey

We look forward to your participation in the in the PA, NJ, DE-Israel Life Sciences Conference.

To help ensure that the program meets your needs and is attended by appropriate representatives from the life sciences industry, funding organizations and other strategic partners from our region that are well-matched to your business, AICC is seeking your input.

Please respond to this questionnaire and return it to the Israel Export Institute at (add contact information) no later than Aug14th, 2008.

  1. Key Contact’s Information
  2. Company Name:Protalix
  3. Company Technology: Device,
    Biotechnology,
    Pharmaceuticals,
    Healthcare IT
  4. Company Site:
  5. Delegate’s Name:Shlomzion Shen
  6. Delegate’s Title:Director of Business Development
  7. Delegate’s Phone:972-54-2239004
  8. Company description and background and current financials - including investments. (50 word limit)

Protalix is a publicly traded clinical stage biopharmaceutical company (AMEX: PLX) that is focused on developing and manufacturing of recombinant therapeutic proteins. Protalix uses its proprietary plant cell culture and bioreactor technology for the expression of recombinant therapeutic proteins, and is currently developing several such biotherapeutic products. Our patented plant cell system enables the expression in plant cells of specific human genes, most often genes coding expression for proteins of pharmaceutical or therapeutic value. Subsequently, the expressed protein is extracted from the plant cells and purified to a clinical grade.Protalix established a bio-manufacturing plant and state-of-the-art research facility for the development and large scale production of clinical grade proteins in Israel. Our dual strategic approach allows the company to leverage its unique plant cell bioreactor system in order to generate revenue from: (I) Commercializing of innovative biopharmaceuticals developed in Protalix and (II) Partnerships for the development and production of biotherapeutics. We are seeking to form partnerships with bio-pharmaceutical companies for co-development and production of various complex recombinant therapeutic proteins to penetrate a wide range of target diseases and therapeutic markets and that can benefit from the significant cost, intellectual property and other competitive advantages of our ProCellEx protein expression.

  1. Product description including, target market, stage of development and major accomplishments to date (50 word limit)

Protalix lead product development candidate, is prGCD, an enzyme for the treatment of Gaucher disease. Upon our successful completion of phase I clinical trial, Protalix received approval from the FDA to initiate a pivotal phase III clinical trial under SPA agreement. Protalix’ Phase III clinical trial for Gaucher disease is currently ongoing in major leading medical centers world wide. Furthermore, we have initiated a follow-on extension study with enrollment of our first patient in June 2008. Additionally, a switch over trial is anticipated to initiate in Q3 2008 in order to evaluate safety and efficacy of prGCD in patients receiving treatment with Cerezyme. This study is expected to enhance the marketing potential of prGCD. Protalix’, innovative product pipeline, includes additional proprietary therapeutic protein candidates which will enable us to progress preclinical studies for various products during 2008.

  1. Are you seeking an investment? Y/N
  2. Amount$
  3. Timeframe:
  4. Purpose:
  5. Preferred Source:
  6. Listed below is a sampling of the key Life-Science constituents in our area. Based on your research, please identify all the organizations (whether or not listed) that you believe are appropriate prospects for a strategic partnership with your company.
  7. For each company, please tell us what division or department within the company is best suited to a collaboration with your company
  8. For each department, please identify the title of the most appropriate contact for your meeting (examples-Director of R&D, Global Business Development, Medical Specialist, Licensing Officer)

Arrow International:

AstraZeneca Pharmaceuticals LP: Business Decelopment/Licensing/ Biologics

Baxter Healthcare Corp:

Business Development/Licensing/ Biologics

Bristol-Myers Squibb Co.:

Cephalon Inc.:

Covatec:

ENDO Pharmaceuticals:

Genzyme Corp.:

GlaxoSmith-Kline: Business Decelopment/Licensing/ Biologics

Impax Laboratories Inc.:

Johnson& Johnson

Centocor Biologics: Business Decelopment/Licensing/ Biologics

Ethicon LLC:

Janssen Pharmaceutical Inc:

McNEIL-PPC Inc.:

Ortho BioTech Inc.: Business Decelopment/Licensing/ Biologics

Ortho Clinical Diagnostics:

Lannett Co. Inc.: Business Decelopment/Licensing/ Biologics/ Biosimilars

Laron Pharmaceuticals Inc.:

Mennen Medical Corp.:

Merck & Co Inc.: Business Decelopment/Licensing/ Biologics

Kensey Nash Corp.:

Novartis Pharmaceuticals Corp.: Business Decelopment/Licensing/ Biologics

Pfizer Inc.:

Quest Diagnostics:

Roche

Pharmaceuticals: Business Decelopment/Licensing/ Biologics

Diagnostics:

Sanofi Aventis: Business Decelopment/Licensing/ Biologics

Shire US Inc.:

Siemens Medical Solutions:

ViroPharma Inc.:Business Decelopment/Licensing/ Biologics

West Pharmaceutical Services:

Wyeth Pharmaceuticals: Business Decelopment/Licensing/ Biologics

Zlb Behring LLC: Business Decelopment/Licensing/ Biologics

  1. From the list below, please provide all additional areas for potential collaboration and resource development for your company.
  2. Physicians/Health care practitioners
  3. Reimbursement
  4. Regulatory Issues
  5. Clinical Trials
  6. Healthcare Administrators
  7. Distribution
  8. Technology transfer
  9. Academia
  10. Incubators/Science Parks
  11. Licensing
  12. Medical Advisory
  13. Financial Advisory
  14. Clinical Development
  15. Intellectual Property
  16. Staffing
  17. Others (please list) generic companies interested in Biosimilars production technologies